Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Diurnal to participate in Edison “Open House”

24th Jan 2022 07:00

RNS Number : 3006Z
Diurnal Group PLC
24 January 2022
 

24 January 2022

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Diurnal to participate in Edison Group's Global Healthcare "Open House" virtual conference

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be participating at Edison Group's Global Healthcare "Open House" conference taking place virtually between 25-27 January 2022. Investors can register to attend here: https://www.edisongroup.com/event/edison-open-house-global-healthcare-2022/.

 

Martin Whitaker, Chief Executive Officer of Diurnal, will be presenting an overview of the Company which will be available on demand from 08:00 GMT on 25 January 2022. Martin Whitaker and Richard Bungay, Diurnal's Chief Financial Officer, will also be conducing 1x1 meetings with investors.

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

 

Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea

 

Corporate Broking: Nick Adams

 

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

 

About Diurnal Group plc:

 

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKNBDOBKDCDB

Related Shares:

DNL.L
FTSE 100 Latest
Value8,809.74
Change53.53